All questionsPharmacology: Enhertu (fam-trastuzumab deruxtecan-nxki), all indications5 questions · 1 sourceMechanismHow does Enhertu work (mechanism of action)?“Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.” (opens the source at this quote in a new tab)CopyFlag“Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase I inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease- cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.” (opens the source at this quote in a new tab)CopyFlagHow many deruxtecan molecules are attached to each Enhertu antibody?“Approximately 8 molecules of deruxtecan are attached to each antibody molecule.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Enhertu?“ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL with a pH of 5.5. The resulting solution is administered by intravenous infusion following dilution.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsWhat is the half-life of Enhertu?“The median elimination half-life of fam-trastuzumab deruxtecan-nxki is 5.4 to 5.7 days. The estimated systemic clearance of fam-trastuzumab deruxtecan-nxki is 0.4 L/day (24%). The median elimination half-life of DXd is 5.4-6.1 days. The estimated systemic clearance of DXd is 18 L/h (28%).” (opens the source at this quote in a new tab)CopyFlag“Accumulation of fam-trastuzumab deruxtecan-nxki is approximately 1.4-fold at steady-state (Cycle 3).” (opens the source at this quote in a new tab)CopyFlagHow is Enhertu metabolized?“Metabolism The monoclonal antibody is expected to be degraded into small peptides and amino acids via catabolic pathways. DXd is primarily metabolized by CYP3A4.” (opens the source at this quote in a new tab)CopyFlag